Panome Bio at US HUPO 2025: Powering Discovery with Integrated Multi-omics
Panome Bio was proud to return for our third consecutive year as an exhibitor at US HUPO 2025, held this February in Philadelphia. As always, the conference provided an outstanding platform to engage with the proteomics and broader omics community, and this year’s discussions around multi-omic integration, clinical applications, and analytical accuracy hit especially close to home.
Our team contributed to several impactful sessions that showcased the power of combining metabolomics, proteomics, and targeted profiling to address complex biological questions:
Poster Presentations
Monday, February 24
Cohort-Based Integrated Multiomics from Single Sample Blood Draws Provides Comprehensive Holistic Phenotypic Insights
Presented by: Dr. Ethan Stancliffe
This poster demonstrated how Panome Bio’s streamlined sample workflow enables deep, multidimensional phenotyping from a single blood draw—ideal for scalable cohort studies and translational research.
Tuesday, February 25
Predicting Poor Outcomes in COVID-19 Patients Through Integrating Targeted Profiling of Inflammatory Proteins with Untargeted Metabolomics
Presented by: Dr. Adam Richardson
Dr. Richardson shared insights into how combined metabolic and protein profiling can help identify predictive signatures of disease severity, with implications for personalized medicine and triage strategies.
Oral Presentations
Monday, February 24
Multi-Omic Analysis Identifies Modulations in Amino Acid and Fatty Acid Metabolism Associated with Cardiovascular Dysfunction in RAB27a Mutant Mice
Presented by Dr. Calvin Vary | In partnership with MaineHealth
This collaborative study highlighted how integrated metabolomic and proteomic analysis can illuminate molecular changes linked to cardiovascular risk in a genetic mouse model.
Tuesday, February 25
Moving Beyond Coverage: Assessing the Quantitative Accuracy of Affinity and Mass Spec Based Approaches to High-Throughput Proteomics
Presented by: Dr. Ethan Stancliffe
In this talk, Dr. Stancliffe addressed a critical question in the proteomics community—how to balance depth of coverage with quantitative reliability across different platforms.
Throughout the week, we had fantastic conversations with researchers eager to explore how Panome Bio’s Next-Generation Metabolomics, proteomics, and multi-omic capabilities can enhance discovery in disease biology, therapeutic development, and translational research.
As multi-omics continues to move from theory to practice, we’re excited to be a trusted partner helping scientists get more from every sample. Thank you to everyone who joined us in Philadelphia—we’ll see you again at US HUPO 2026!